(NASDAQ: IBRX) Immunitybio's forecast annual revenue growth rate of 109.95% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.08%, and it is also forecast to beat the US market's average forecast revenue growth rate of 24.86%.
Immunitybio's revenue in 2025 is $56,600,000.On average, 7 Wall Street analysts forecast IBRX's revenue for 2025 to be $101,737,761,747, with the lowest IBRX revenue forecast at $93,042,363,899, and the highest IBRX revenue forecast at $108,581,405,666. On average, 7 Wall Street analysts forecast IBRX's revenue for 2026 to be $213,561,390,982, with the lowest IBRX revenue forecast at $130,454,599,077, and the highest IBRX revenue forecast at $277,309,366,938.
In 2027, IBRX is forecast to generate $534,730,575,305 in revenue, with the lowest revenue forecast at $256,324,712,931 and the highest revenue forecast at $788,777,224,445.